Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

I have schizoaffective disorder, bipolar type — a combination of schizophrenia and bipolar disorder — and I agree that this is a monumental development for my community. Historically ...

One such investigative compound currently in clinical trials is an amino acid, N-Acetyl Cysteine (NAC), which appears to reduce the core symptoms of bipolar disorder, schizophrenia, depression ...

Scientists believe they've discovered where the "voices" heard by some people with schizophrenia emanate from using brainwave mapping. As detailed in a new study published in the journal PLOS ...

Researchers Discover a Mechanism That Impairs Synaptic Plasticity in the Brains of Schizophrenia Patients Sep. 4, 2024 — A study mapped genes linked to schizophrenia and uncovered a mechanism ...

Caplyta (lumateperone) was approved for the treatment of schizophrenia in 2019 and for depressive episodes linked to bipolar I or bipolar II disorder (bipolar depression) in 2021. Caplyta can be ...

At 30, John Nash suffered his first bout of full-blown schizophrenia, a disease sometimes called the "cancer of the mind." Aolicai Nash, his wife, was 26 at the time. "I wanted to help him," she ...

About one in 300 people worldwide are affected by schizophrenia, but for decades treatment options have been both static and limited. If the FDA approves the twice-daily pill on Thursday ...

The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...

Hi. I'm Michele Hammer and I have schizophrenia. Schizophrenia is a mental illness that changes the way you think, feel, and act. It's broken down into three separate categories, positive ...

The U.S. Food and Drug Administration late Thursday approved a new kind of drug to treat schizophrenia, a breakthrough after ...